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Abstract
Background—Limited data exist on the impact of the serogroup B meningococcal (MenB) 
vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection. We therefore 
assessed meningococcal carriage following a MenB vaccination campaign in response to a 
university serogroup B meningococcal disease outbreak in 2015.
Methods—A convenience sample of students recommended for vaccination provided 
oropharyngeal swabs and completed questionnaires during four carriage surveys over 11 months. 
Isolates were tested by real-time PCR, slide agglutination, and whole genome sequencing. 
Vaccination history was verified via university records and the state immunization registry.
Results—A total of 4,225 oropharyngeal swabs were analyzed from 3,802 unique participants. 
Total meningococcal and genotypically serogroup B carriage prevalence among sampled students 
were stable at 11–17% and 1.2%–2.4% during each round, respectively; no participants carried the 
outbreak strain. Neither 1–3 doses of MenB-FHbp nor 1–2 doses of MenB-4C was associated with 
decreased total or serogroup B carriage prevalence.
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Conclusions—While few participants completed the full MenB vaccination series, limiting 
analytic power, these data suggest that MenB-FHbp and MenB-4C do not have a large, rapid 
impact on meningococcal carriage and are unlikely to provide herd protection in the context of an 
outbreak response.
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Introduction
In January–May, 2015, six cases of serogroup B meningococcal disease, including one 
death, occurred among undergraduate students at a large Oregon university (~20,000 
undergraduates). One additional, non-fatal case occurred in a close contact of a student. All 
cases were caused by the same strain of Neisseria meningitidis serogroup B: clonal complex 
32, sequence type (ST) 32. In response to the outbreak, local public health officials provided 
the serogroup B meningococcal (MenB) vaccine MenB-4C (Bexsero®, GlaxoSmithKline, 
two-dose series) to a small number of interested students beginning in February 2015. 
Subsequently, mass vaccination campaigns with MenB-FHbp (Trumenba®, Pfizer, three-
dose series recommended for outbreak response) were held in March, May, and October 
2015 and February 2016. MenB-FHbp was also available at local pharmacies throughout this 
time period and during freshmen orientation (June–August 2015). At least 25% of 
undergraduate students received at least one dose of MenB-FHbp or MenB-4C at the mass 
vaccination clinics (Fisher et al., manuscript in preparation); however, due to the many 
additional opportunities for students to receive vaccine, overall vaccination coverage at the 
university was likely substantially higher.
Meningococcal disease is a serious illness with a 10–20% case-fatality ratio; however, only 
433 cases were reported in the United States in 2014 (incidence: 0.18 per 100,000 
population) [1]. In addition to causing disease, meningococci are frequently carried 
asymptomatically in the nasopharynx. Asymptomatic meningococcal carriage is not a risk 
factor for meningococcal disease; rather, carriage and disease are distinct outcomes of 
meningococcal acquisition [2]. However, because carriers are an important source of 
transmission, population meningococcal carriage must be reduced to provide herd protection 
against meningococcal disease. Serogroup C and A conjugate meningococcal vaccines have 
been shown to provide herd protection against the specific serogroups targeted by the 
vaccines [3,4].
In the United States, conjugate meningococcal vaccines that protect against serogroups A, C, 
W, and Y (MenACWY) were approved in 2005 and are routinely administered to 
adolescents [5]. The MenB vaccines MenB-FHbp and MenB-4C were licensed in the US in 
2014–2015 as a 2 (MenB-4C) or 2–3 (MenB-FHbp) dose series for persons aged 10–25 [6]. 
Because these vaccines contain meningococcal outer membrane proteins present in both 
serogroup B and non-serogroup B meningococci, they could potentially impact carriage of 
all meningococci, not just serogroup B. However, only two studies of MenB vaccine impact 
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on meningococcal carriage have been published. One study found an 18% reduction in 
overall meningococcal carriage (95% confidence interval 3–31%) among university students 
vaccinated with MenB-4C; however, no impact on serogroup B carriage was observed [7]. 
The other study assessed carriage following mass vaccination with MenB-FHbp at a 
university; no reduction in overall or serogroup B carriage in the population was observed 
[8].
During the Oregon university outbreak, it was believed that both MenB-FHbp and MenB-4C 
would help protect individual students from developing disease due to the outbreak strain. 
However, it was not known whether MenB vaccination would impact meningococcal 
carriage and transmission to provide herd protection in this population. We implemented a 
meningococcal carriage evaluation in conjunction with the vaccination clinics to assess the 
prevalence of meningococcal carriage in this population and evaluate the impact of the 
vaccination campaign on carriage of (1) any meningococci, (2) serogroup B N. meningitidis, 
and (3) the strain associated with the outbreak.
Methods
This evaluation was considered non-research, public health evaluation by CDC and Oregon 
Health Authority and did not require institutional review for human subjects’ protection. 
Four carriage evaluation rounds were conducted in conjunction with the mass vaccination 
clinics held in March, May, and October 2015 and February 2016. All students at the 
affected university who were recommended to receive MenB vaccine were eligible to 
participate in the carriage evaluation; this included all undergraduate students as well as 
graduate students living in undergraduate dormitories or with medical conditions that 
increase the risk for meningococcal disease (persistent complement component deficiency or 
functional or anatomic asplenia) [6]. Students were eligible to participate in the carriage 
evaluation regardless of whether they had received MenB vaccine and could participate in 
multiple evaluation rounds, but only once per round.
A convenience sample of students was recruited at mass vaccination clinics during a 15-
minute post-vaccination waiting period and at high-traffic sites on the university campus. 
Participants provided informed consent and completed a short questionnaire assessing 
demographics, vaccination status, and risk factors for meningococcal disease. Trained staff 
swabbed each participant’s tonsils and posterior oropharynx using a polyester double swab 
(BD BBL; Franklin Lakes, NJ, US). Swabs were immediately plated on Modified Thayer-
Martin (MTM) agar (BD BBL; Franklin Lakes, NJ, US) and stored at room temperature in 
Mitsubishi boxes in CO2 atmosphere for a maximum of 4 hours before transport to the 
laboratory, where they were incubated at 37°C with 5% CO2.
The plates were examined for growth at 24, 48, and 72 hours. Colonies with typical 
Neisseria morphology were subcultured onto blood agar (BD BBL; Franklin Lakes, NJ, US) 
and tested by Gram Stain (BD BBL; Franklin Lakes, NJ, US); oxidase test (Hardy 
Diagnostics; Santa Maria, CA, US) was performed on subcultured colonies of all Gram-
negative diplococci from the blood agar plate. When oxidase-positive, Gram-negative 
diplococci were found, API NH strip (bioMerieux; Durham, NC, US) and real-time 
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polymerase chain reaction (rt-PCR) for sodC were used to confirm species [9]; discrepancies 
between tests were resolved through whole genome sequencing (WGS). Remaining colonies 
were subcultured and further characterized by slide agglutination (SASG) using 
commercially available antisera (DIFCO, BD BBL; Franklin Lakes, NJ, US) for expression 
of the serogroup A, B, C, W, X, and Y capsule antigens [10]; and singleplex rt-PCR for 
serogroup A, B, C, W, X, and Y capsule biosynthesis genes [10,11]. Isolates were classified 
as nongroupable by rt-PCR if the capsule biosynthesis genes for these six serogroups were 
not detected. Isolates negative for serogroup A, B, C, W, X, and Y capsule antigen 
expression by SASG were classified as “other” as these isolates could either be 
phenotypically nongroupable or could express the non-disease associated serogroup E or Z 
capsule antigens.
WGS was performed on serogroup B isolates identified using SASG or rt-PCR to determine 
similarity to the university outbreak strain. Genomic DNA was extracted using the 
ArchivePure™ DNA purification kit (5 Prime, Gaithersburg, MD, US) to create libraries for 
sequencing using the NEBNext Ultra DNA library preparation kit (New England Biolabs 
Inc., Ipswich, MA, US). Sequencing was performed using an Illumina MiSeq with MiSeq 
250-bp paired-end kits (Illumina, San Diego, CA, US). Raw sequence reads with high 
quality were trimmed and assembled using CLC Bio Genomics Workbench (v8.5.1, Qiagen, 
Waltham, MA, US) as previously described [12]. A BLAST search was used on the 
assembled genomes and compared with PubMLST to identify multilocus sequence typing 
(MLST) alleles [13,14]. For serogroup B isolates, porA and porB antigenic sequences were 
also assessed to characterize similarity to the outbreak strain.
Student meningococcal vaccination history was verified using university student health 
medical records, vaccination clinic attendance registers, and the Oregon state immunization 
registry, ALERT IIS.
Statistical analysis was conducted using SAS 9.3 (Cary, NC). We performed descriptive 
statistics of patient characteristics and calculated prevalence ratios (PRs) for associations 
between participant characteristics and overall or serogroup B meningococcal carriage. 
Bivariate and multivariable analysis was conducted using Poisson regression with 
generalized estimating equations (GEE) to account for individuals participating in multiple 
rounds. Where possible, we used an unstructured correlation matrix; for models that did not 
converge we instead used an autoregressive correlation matrix. Multivariable models 
included all variables that were significant (p<0.05) in bivariate analysis as well as MenB 
vaccination status. A descriptive analysis of within-individual changes in carriage was 
performed for individuals who participated in multiple carriage evaluation rounds. We 
included only MenB vaccine doses received ≥14 days prior to carriage evaluation 
participation to ensure that we did not include doses that had been received too recently to 
have stimulated an immune response.
Results
A total of 4,526 participants were enrolled over four carriage evaluation rounds. Of these, 
301 were excluded: 14 due to ineligibility; 284 because their swab could not be tested due to 
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laboratory equipment failure (n=265), plating error, contamination, or missing sample; and 3 
because consent forms or questionnaires were missing. This resulted in a total of 4,225 
oropharyngeal swabs analyzed from 3,802 unique participants. A total of 328 students 
participated in more than one evaluation round: 247 participated in two rounds, 77 in three 
rounds, and four participated in four rounds. Table 1 summarizes participant characteristics 
(participants missing information for each characteristic are not shown).
No individual source of meningococcal vaccination history was complete; however, based 
on student self-report and vaccine history abstraction, MenACWY vaccination status could 
be assigned for 3431/4225 (81%) participants and MenB vaccination status for 3732/4225 
(88%) (Table 1). MenACWY vaccination status was validated from written records for 
2854/4225 participants (68%) and MenB vaccination status was validated for 3063/4225 
(72%); remaining participants had vaccination status assigned based on self-report alone. Of 
participants with assigned MenACWY vaccination status, 82% had received MenACWY 
vaccine; of participants with assigned MenB vaccination status, 57% had received one or 
more doses of a MenB vaccine ≥14 days prior to carriage evaluation participation (Table 1). 
Including both documented and self-reported vaccination status, 64 participants (1.7%; all 
unique participants) received a complete three-dose series of MenB-FHbp and 135 (3.6%; 
133 unique participants) received a complete two-dose series of MenB-4C (Table 1).
Meningococcal carriage was found in 11%–17% of participants in each round, with highest 
carriage in rounds 2 and 4 (Table 2). Most carried meningococci did not express serogroup 
A, B, C, W, X, or Y capsule antigens (per SASG) and were genotypically (by rt-PCR) 
nongroupable (Table 2). In each round, approximately 1%–2% of students carried 
genotypically serogroup B N. meningitidis and bacteria expressing the serogroup B capsule 
were carried by <1% of participants (Table 2). Carriage of serogroups C, W, X, and Y was 
<1% by rt-PCR and <0.5% by SASG (Table 2).
MLST sequence type could be assessed through WGS for 78/79 serogroup B isolates. Two 
ST-32 serogroup B isolates were identified (Table 3); however, comparison of porA and 
porB antigenic sequences demonstrated that the carried isolates did not match the outbreak 
strain. The remaining 76 serogroup B isolates represented a wide variety of STs. ST-136 was 
the most frequently detected (n=27) (Table 3).
In bivariate analyses, increased carriage of any N. meningitidis was associated with 
participation during rounds 2 or 4; male gender; sophomore or junior year; age 19–22 years; 
living off-campus; living in an apartment, house, sorority, or fraternity; having ≥3 
roommates; upper respiratory tract infection symptoms in the past 30 days; recent smoking 
or second-hand smoke exposure; and attending parties, bars, clubs, or other social mixing 
events ≥ once per week (Table 4). Living with family and recent antibiotic use were 
associated with lower carriage (Table 4). In multivariable analysis, male sex, being 20 years 
of age, smoking, and attending social mixing events ≥ once per week remained associated 
with increased carriage and recent antibiotic use with decreased carriage (Table 4).
Receipt of two MenB-4C doses was associated with increased carriage in bivariate analysis; 
however, no association between meningococcal carriage and MenB-FHbp or MenB-4C was 
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observed in multivariable analysis (Table 4). Further analysis showed that MenB-4C receipt 
was associated with increased frequency of social mixing and having ≥3 roommates (data 
not shown). Similar results were obtained when the analysis was restricted to participants for 
whom MenB vaccinations could be verified through university records or the state 
immunization registry (data not shown).
Associations between participant characteristics and carriage of genotypically serogroup B 
meningococci were also assessed. Round 2; age 19, 20, or 22 years; having ≥3 roommates; 
smoking; and attending social mixing events 2–3 times per week were associated with 
increased serogroup B carriage in bivariate analysis (Table 5). Smoking and social mixing 
remained associated with increased serogroup B carriage in the multivariable analysis (Table 
5). Receipt of MenB-FHbp or MenB-4C was not associated with serogroup B carriage in 
either bivariate or multivariable analysis (Table 5). Similar results were again obtained when 
the analysis was restricted to participants for whom MenB vaccinations could be verified 
through university records or the state immunization registry (data not shown).
We also evaluated changes in carriage between rounds for individuals who participated in 
multiple rounds. After classifying participants by the type and number of MenB vaccine 
doses received prior to their second participation time point, only 18 individuals in the 
longitudinal analysis had not received any MenB vaccine doses by their second round of 
participation (Table 6). None of these 18 individuals carried N. meningitidis during either 
their first or their second round of participation (Table 6), meaning that carriage loss among 
vaccinated and unvaccinated individuals could not be compared. Meningococcal carriage 
acquisition was observed in 5–11% of individuals who had received 1–3 doses of MenB-
FHbp or 1–2 doses of MenB-4C (Table 6); however, carriage acquisition among vaccinated 
and unvaccinated groups also could not be compared due to small numbers. Three 
individuals acquired genotypically serogroup B (phenotypically nongroupable) 
meningococci; all other individuals with new carriage acquired genotypically nongroupable 
meningococci.
Discussion
The four meningococcal carriage evaluation rounds spanned 11 months, beginning in the 
middle of the outbreak and ending nine months after the last outbreak case occurred. During 
this period, no decrease in overall or serogroup B meningococcal carriage was observed 
among sampled students, suggesting that the mass vaccination campaign at the university 
did not substantively reduce meningococcal transmission within the population. Overall 
meningococcal carriage was lower during the third evaluation round; however, this round 
occurred shortly after students returned from summer break, a period during which more 
limited opportunities for student interaction may have resulted in reduced meningococcal 
transmission within the population. By round 4 carriage had increased above baseline 
carriage in round 1. In the multivariable analysis, differences in carriage by round were not 
statistically significant.
Our analysis also did not reveal any association between vaccination and overall or 
serogroup B meningococcal carriage at the individual level, although the low carriage 
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prevalence of serogroup B meant that power to detect associations with serogroup B carriage 
was limited. Overall, these findings suggest that neither MenB-4C nor MenB-FHbp had a 
large, rapid impact on meningococcal carriage that could provide herd protection in the 
context of a meningococcal disease outbreak. However, as relatively few participants had 
received MenB-4C or completed a full MenB vaccination series with either vaccine, power 
to detect moderate changes in carriage following receipt of the full vaccination series was 
also limited. It remains possible that the MenB vaccines could have a longer-term impact on 
carriage following administration of the complete vaccination series. Furthermore, MenB 
vaccination is still the best way to provide individual protection for the duration of the 
outbreak to people in the affected population.
Carriage of the outbreak strain was not detected during any round of the carriage evaluation. 
However, as three outbreak cases occurred after the first carriage evaluation round occurred, 
it is clear that the outbreak strain was still circulating within the university population, but 
with a low enough prevalence that it was not observed in the sampled population. Low 
outbreak strain carriage has been found in other meningococcal disease outbreaks [8,15], 
and suggests that acquisition of pathogenic strains associated with outbreaks is more likely 
to lead to disease and less likely to lead to carriage; or if carriage is established, the duration 
of carriage may be relatively short [16].
The meningococcal carriage prevalence of 11–17% observed here is similar to that found in 
another recent university carriage evaluation in the United States [8]; however, both studies 
showed higher carriage prevalence than that observed in other recent US carriage evaluations 
[15,17,18]. These other evaluations recruited participants from high schools [17] or the 
general population [15,18] rather than restricting participation to university students. 
Meningococcal carriage has previously been associated with social mixing [19] and age 
[20,21], so it is not surprising that relatively high carriage was detected among university 
undergraduates. As very little carriage of serogroup B ST-32 was detected, it is also unlikely 
that the relatively high carriage prevalence is related to the historically higher rates of 
meningococcal disease due to serogroup B ST-32 in Oregon [22]. Substantially higher 
carriage prevalence of ≥30%, including up to 18% carriage prevalence of disease-associated 
serogroups, has been detected among university students in the United Kingdom [7,23].
Interestingly, both our evaluation and the recent evaluation by Soeters et al. [8] detected 
carriage prevalence of N. meningitidis expressing the B, C, or Y capsular polysaccharide 
that was similar to or lower than that observed previously in the United States [15,17]. The 
higher total meningococcal carriage prevalence in our sample was instead due to high 
carriage of phenotypically and genotypically nongroupable meningococci, which were 
detected in 10–17% of participants in each round. The low carriage of encapsulated 
serogroup C, W, and Y meningococci (0–0.4% of participants per round) in a setting of high 
overall meningococcal carriage could be related to routine use of MenACWY vaccines in 
US adolescents. However, due to the extremely low carriage of these serogroups among our 
participants, we could not assess the potential relationship between MenACWY vaccination 
and carriage.
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Vaccinated and unvaccinated students included in this observational evaluation may be 
substantially different in characteristics that may affect risk of carriage. Indeed, students 
who received MenB-4C reported a significantly higher frequency of social mixing than 
students who did not receive a MenB vaccine. While we controlled for confounding by 
assessing meningococcal carriage risk factors through our questionnaire and including these 
factors in the multivariable analysis, unidentified confounding could obscure an association 
between MenB vaccination and meningococcal carriage. We also had limited longitudinal 
data to assess meningococcal carriage acquisition and loss in our participants, so we could 
not assess whether the MenB vaccines impact meningococcal carriage loss or acquisition 
more than overall carriage.
Although analytical power was limited by the relatively few participants who completed a 
MenB vaccination series, our findings suggest that neither MenB-FHbp nor MenB-4C 
vaccination has a large, rapid effect on meningococcal carriage. This suggests that using 
these vaccines during a meningococcal disease outbreak is unlikely to rapidly provide herd 
protection in the target population. Without herd protection, high vaccination coverage in the 
population at risk is essential to help protect each individual at increased risk; meanwhile, 
chemoprophylaxis of close contacts of meningococcal disease cases remains critical to 
reduce transmission and prevent secondary cases [5]. This evaluation will inform MenB 
vaccination guidelines; however, additional information on the effectiveness, coverage, and 
duration of protection afforded by both MenB vaccines is needed to develop the best 
guidelines for their use.
Acknowledgments
Funding: No external funding was received to conduct this evaluation.
This work was supported by the Centers for Disease Control and Prevention. The Centers for Disease Control and 
Prevention have a cooperative research and development agreement with Pfizer Vaccine to monitor vaccine antigens 
among invasive meningococcal strains in the US; this activity is separate from the work described in this article. 
The authors have no other potential conflicts of interest to report.
Additional members of the Oregon Meningococcal Carriage Team include: Kristina Angelo, Amy Blain, Pam 
Cassiday, Shankar Changayil, Elizabeth Chandler Church, Kasey Diebold, Sinmisola Ewumi, Amanda Faulkner, 
Helen Fisun, Holly Haberman, Brian Harcourt, Sterling Haring, Lauren Hughes, Sandeep Joseph, Nivritti Kumaran, 
Adria Lee, Tanya Lennon, Ruth Link-Gelles, Lihan (Diana) Lu, Jessica Marcinkevage, Leonard Mayer, Jenny 
Milucky, Christine Miner, Jennifer Nelson, Manisha Patel, Simon Paulos, Veronica Pinell-McNamara, Conrad 
Quinn, Gowrisankar Rajam, Romany Redman, Adam Retchless, Mariana Rosenthal, Vera Semenova, Tami Skoff, 
Elizabeth Smulian, Toscha Stanley, Erin Stratton, Pam Talley, Tejpratep Tiwari, Karrie-Ann Toews, and Matt 
Westercamp (CDC); Paul Cieslak, Malini DeSilva (Oregon Health Authority); Nick Alviani, Frances Biel, Bailey 
Burkhalter, Matt Francis, Phebe Howe, Esther Jackson, Tina Johnson, Patrick Luedtke, Zach Manning, Ester Muno, 
Todd Roberts, Zack Roberts (Lane County Department of Health and Human Services; and Michael Eyster and 
Charles Hollands (University of Oregon).
We thank Ivy Adekoya, Elizabeth Briere, Karen Craggette, Krista Dillon, Vernette Seays-Briley, Vicki Strand, 
Ashley Tate, and Lakeisha Swanson for their assistance with carriage evaluation logistics and coordination with the 
vaccination clinics; LeAnn Gutierrez, Debra McLaughlin, Rebecca Schunicht, and Ceara Wilson for assistance with 
vaccination history abstraction at University of Oregon Student Health; Emilio DeBess, Heather Jamieson, Tessa 
Jaqua, Rob Laing, Keenan Williamson, and Alexia Zhang for assistance recruiting evaluation participants; Jeff Lang 
for assistance identifying carriage evaluation staff; and Donna Garner for assistance with data and record storage 
and transmission. We would also like to thank James Mough, Anne Robertson, Tanna Gallup, Ariana White, Liz 
Silverman, and the staff of the University Health Center Laboratory at the University of Oregon as well as Mary 
Casas, Rick Wirtz, Robert Liao, Judy January, Darcie Westerman, Sierra Hillmeyer, Cindy Glover, Mark Dwyer, 
Anita Barker, Lauri Swearingen, Timmie Bigornia, and PeaceHealth Laboratories for providing space and logistical 
support for isolate growth and testing in the field.
McNamara et al. Page 8
J Infect Dis. Author manuscript; available in PMC 2018 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The findings and conclusions in this report are those of the authors and do not necessarily represent the official 
position of the Centers for Disease Control and Prevention.
References
1. Adams D, Thomas KR, Jajosky RA, et al. Summary of notifiable infectious diseases and conditions 
– United States, 2014. MMWR. 2016; 63(54):1–152.
2. Trotter C, Maiden M. Meningococcal vaccines and herd immunity: lessons learned from serogroup 
C conjugate vaccination programs. Expert Rev Vaccines. 2009; 8(7):851–861. [PubMed: 19538112] 
3. Maiden MCJ, Stuart JM. for the UK Meningococcal Carriage Group. Carriage of serogroup C 
meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002; 
359(9320):1829–1830. [PubMed: 12044380] 
4. Kristiansen PA, Diomandé F, Ky Ba A, et al. Impact of the serogroup A meningococcal conjugate 
vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013; 56(3):354–363. 
[PubMed: 23087396] 
5. CDC. Prevention and control of meningococcal disease: Recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR. 2013; 62(RR-2):1–28.
6. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal 
vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: 
Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015; 
64(22):608–612. [PubMed: 26068564] 
7. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY 
glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-
blind, phase 3 randomised clinical trial. Lancet. 2014; 384(9960):2123–2131. [PubMed: 25145775] 
8. Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to 
a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college — 
Rhode Island, 2015–2016. Clin Infect Dis. 2017; 64(8):1115–1122. [PubMed: 28158417] 
9. Dolan Thomas J, Hatcher CP, Satterfield DA, et al. sodC-Based real-time PCR for detection of 
Neisseria meningitidis. PLoS one. 2011; 6(5):e19361. [PubMed: 21573213] 
10. Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide 
agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 
2004; 42(1):320–8. [PubMed: 14715772] 
11. Wang X, Theodore MJ, Mair R, et al. Clinical validation of multiplex real-time PCR assays for 
detection of bacterial meningitis pathogens. J Clin Microbiol. 2012; 50(3):702–708. [PubMed: 
22170919] 
12. Kretz C, Retchless A, Sidikou F, et al. Whole genome characterization of the emerging epidemic of 
meningococcal serogroup C and resurgence of serogroup W in Niger, 2015. Emerg Infect Dis. 
2016; 22(10):1762–1768. [PubMed: 27649262] 
13. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the 
identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci. 
1998; 95(6):3140–3145. [PubMed: 9501229] 
14. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population 
level. BMC Bioinformatics. 2010; 11:595. [PubMed: 21143983] 
15. Weiss D, Stern EJ, Zimmerman C, et al. Epidemiologic investigation and targeted vaccination 
initiative in response to an outbreak of meningococcal disease among illicit drug users in 
Brooklyn, New York. Clin Infect Dis. 2009; 48(7):894–901. [PubMed: 19231975] 
16. Marks MI, Frasch CE, Shapera RM. Meningococcal colonization and infection in children and 
their household contacts. American J Epid. 1979; 109(5):563–571.
17. Harrison LH, Shutt KA, Arnold KE, et al. Meningococcal carriage among Georgia and Maryland 
high school students. J Infect Dis. 2015; 211(11):1761–1768. [PubMed: 25505298] 
18. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant Neisseria 
meningitidis in North America. New Engl J Med. 2009; 360(9):886–892. [PubMed: 19246360] 
19. MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British 
teenagers. Emerg Infect Diseases. 2006; 12(6):950–957. [PubMed: 16707051] 
McNamara et al. Page 9
J Infect Dis. Author manuscript; available in PMC 2018 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
20. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a 
systematic review and meta-analysis. Lancet ID. 2010; 10:853–861.
21. Jeppesen CA, Snape MD, Robinson H, et al. Meningococcal carriage in adolescents in the United 
Kingdom to inform timing of an adolescent vaccination strategy. J Infect. 2015; 71:43–52. 
[PubMed: 25709085] 
22. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease 
epidemiology in the United States, 1998–2007: Implications for prevention of meningococcal 
disease. Clin Infect Dis. 2010; 50(2):184–191. [PubMed: 20001736] 
23. Ala’Aldeen DAA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university students, 
United Kingdom. Emerg Infect Dis. 2011; 17(9):1762–1763. [PubMed: 21888817] 
McNamara et al. Page 10
J Infect Dis. Author manuscript; available in PMC 2018 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Summary
Following a serogroup B meningococcal disease outbreak at an Oregon university, a 
meningococcal carriage evaluation was conducted in conjunction with a MenB-FHbp and 
MenB-4C vaccination campaign. Neither vaccine was associated with reduced 
meningococcal carriage among participants.
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Table 3
Genotypic and phenotypic serogroup determination, clonal complex, and sequence type of carried N. 
meningitidis identified as serogroup B by real time PCR (rt-PCR) (N=781) isolated from carriage evaluation 
participants at an Oregon university, March 2015–February 2016
N Genotypic serogroup (rt-PCR) Phenotypic serogroup (SASG) Clonal complex ST
1 B NG CC1117 11855
1 B NG CC1157 1157
2 B B CC162 162
1 B NG CC162 2153
1 B B CC174 1466
2 B B CC213 213
5 B NG CC213 213
1 B B CC213 3496
1 B NG CC213 11852
1 B NG CC269 3091
1 B B CC32/ET-5 322
1 B NG CC32/ET-5 322
1 B B CC32/ET-5 8758
2 B NG CC32/ET-52 11395
3 B NG CC35 35
2 B NG CC35 11392
5 B NG CC41/44/Lineage 3 44
5 B B CC41/44/Lineage 3 136
22 B NG CC41/44/Lineage 3 136
6 B NG CC41/44/Lineage 3 409
1 B NG CC41/44/Lineage 3 1097
1 B B CC41/44/Lineage 3 1489
1 B NG CC41/44/Lineage 3 5881
1 B NG CC461 1946
1 B NG CC461 11861
2 B NG CC4821 11858
1 B NG CC53 53
2 B NG CC865 865
1 B NG unassigned 8537
1 B B unassigned 9069
1 B NG unassigned 11294
1 B B unassigned 11860
1One isolate (genotypically serogroup B, phenotypically NG) excluded as clonal complex and ST could not be determined
2Carried ST-32 isolates were not closely related to isolates from outbreak cases based on comparison of PorA and PorB antigenic sequences
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